Genomic Valley Biotech
GENOMICVALLEYBIOTECHLTD NSE
Genomic Valley Biotech
HealthcareNSE: GENOMICVALLEYBIOTECHLTD BSE: 539206 Biotechnology
Key Fundamentals
MicrocapBiotechnologyHealthcareMarket Cap
₹9.60 Cr
Volatility
Moderate
P/E Ratio
450
EBITDA
₹0.05 Cr
Return on Equity
9.13%
Debt to Equity
0
Book Value
₹12.85
EPS
₹0.42
52W High
₹41
52W Low
₹20.1
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company is almost debt free.
Weaknesses
5- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 5.15% over past five years.
- Company has a low return on equity of 3.68% over last 3 years.
- Company has high debtors of 3,136 days.
- Promoter holding has decreased over last 3 years: -21.1%
Growth Rate
Revenue Growth
-66.25% lower than
3Y
Net Income Growth
-92.5% lower than
3Y
Cash Flow Change
250% higher than
3Y
ROE
—
ROCE
—
EBITDA Margin (Avg.)
-64.61% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.06 | 0.07 | 0.04 | 0 | 0.16 | 0.21 | 0.22 | 0.26 | 0.09 | 0.09 | 0.05 | 0.04 | 0.04 |
| Expenses | 0.03 | 0.05 | 0.02 | 0.04 | 0.03 | 0.07 | 0.06 | 0.26 | 0.06 | 0.09 | 0.04 | 0.04 | 0.02 |
| Operating Profit | 0.03 | 0.02 | 0.02 | -0.04 | 0.13 | 0.14 | 0.16 | 0 | 0.03 | 0 | 0.01 | 0 | 0.02 |
| OPM % | 50% | 28.57% | 50% | — | 81.25% | 66.67% | 72.73% | 0% | 33.33% | 0% | 20% | 0% | 50% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0.03 | 0.02 | 0.02 | -0.04 | 0.13 | 0.15 | 0.16 | 0 | 0.03 | 0 | 0.01 | 0 | 0.02 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — | 0% | — | 0% | — | 0% |
| Net Profit | 0.03 | 0.02 | 0.02 | -0.04 | 0.13 | 0.15 | 0.16 | -0.08 | 0.02 | 0 | 0.01 | -0.01 | 0.01 |
| EPS in Rs | 0.1 | 0.07 | 0.07 | -0.13 | 0.43 | 0.49 | 0.52 | -0.26 | 0.07 | 0 | 0.03 | -0.03 | 0.03 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.03 | 0.11 | 0.44 | 0.59 | 0.99 | 0.85 | 0.21 | 0.07 | 2.72 | 0.17 | 0.84 | 0.27 | 0.22 |
| Expenses | 0.07 | 0.54 | 0.48 | 0.49 | 0.57 | 0.3 | 0.34 | 0.45 | 1.84 | 0.15 | 0.4 | 0.23 | 0.19 |
| Operating Profit | -0.04 | -0.43 | -0.04 | 0.1 | 0.42 | 0.55 | -0.13 | -0.38 | 0.88 | 0.02 | 0.44 | 0.04 | 0.03 |
| OPM % | -133.33% | -390.91% | -9.09% | 16.95% | 42.42% | 64.71% | -61.9% | -542.86% | 32.35% | 11.76% | 52.38% | 14.81% | 13.64% |
| Other Income | 0.07 | 0.16 | 0.01 | 0.03 | 0.01 | 0.01 | 0 | 0.5 | -0.22 | 0 | 0 | 0 | 0 |
| Interest | 0.03 | 0.02 | 0 | 0 | 0 | 0.18 | 0.18 | 0.04 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.01 | 0.05 | 0.04 | 0.08 | 0.19 | 0.18 | 0.19 | 0.08 | 0.01 | 0 | 0 | 0 | 0 |
| PBT | -0.01 | -0.34 | -0.07 | 0.05 | 0.24 | 0.2 | -0.5 | 0 | 0.65 | 0.02 | 0.44 | 0.04 | 0.03 |
| Tax % | 0% | -2.94% | 0% | 40% | 0% | -40% | 12% | — | 0% | 0% | 20.45% | 25% | — |
| Net Profit | -0.01 | -0.33 | -0.07 | 0.03 | 0.23 | 0.29 | -0.56 | -0.01 | 0.65 | 0.02 | 0.36 | 0.03 | 0.01 |
| EPS in Rs | -0.03 | -1.08 | -0.23 | 0.1 | 0.75 | 0.95 | -1.83 | -0.03 | 2.13 | 0.07 | 1.18 | 0.1 | 0.03 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 |
| Reserves | 1.84 | 1.51 | 1.44 | 1.47 | 1.71 | 1.99 | 1.43 | -0.18 | 0.47 | 0.49 | 0.84 | 0.87 |
| Borrowings | 0.75 | 0.75 | 0.75 | 0.75 | 1.48 | 1.48 | 1.55 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0.8 | 0.73 | 0.78 | 1.41 | 0.94 | 1.49 | 1.59 | 0.92 | 0.9 | 0.79 | 0.47 | 0.33 |
| Total Liabilities | 6.44 | 6.04 | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.36 | 4.25 |
| Fixed Assets | 3.15 | 3.18 | 3.63 | 4.12 | 4.31 | 4.47 | 5.86 | 1.75 | 0 | 0 | 0.01 | 0 |
| CWIP | 0 | 0 | 0 | 0.38 | 0.49 | 0.49 | 0.49 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.55 | 0.11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0 | 0 |
| Other Assets | 2.74 | 2.75 | 2.39 | 2.18 | 2.38 | 3.05 | 1.27 | 2.04 | 4.42 | 4.31 | 4.35 | 4.25 |
| Total Assets | 6.44 | 6.04 | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.36 | 4.25 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0.09 | -0.69 | 0.35 | 0.87 | -1.04 | 0.44 | 1.48 | -2.13 | -0.78 | -0.02 | 0.03 | -0.02 |
| Investing | -0.65 | 0.53 | -0.31 | -0.91 | 0.37 | -0.47 | -1.58 | 3.67 | 1.52 | -0.02 | 0.01 | 0 |
| Financing | 0 | 0 | 0 | 0 | 0.73 | 0 | 0.07 | -1.55 | -0.7 | 0 | 0 | 0 |
| Net Cash Flow | -0.56 | -0.16 | 0.04 | -0.04 | 0.06 | -0.04 | -0.03 | -0.01 | 0.04 | -0.04 | 0.04 | -0.02 |
| Free Cash Flow | -0.05 | -0.77 | -0.15 | -0.07 | -0.68 | -0.04 | -0.1 | 3.22 | 0.7 | -0.02 | 0.02 | -0.02 |
| CFO/OP | -225 | 160 | -875 | 870 | -248 | 80 | -1,138 | 561 | -89 | -100 | 27 | -25 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0 | 0 | 0 | 12.37 | 22.12 | 42.94 | 104 | 0 | 298 | 5,432 | 960 | 3,136 |
| Inventory Days | 0 | 0 | — | — | — | — | 0 | — | 0 | — | 487 | — |
| Days Payable | — | — | — | — | — | — | — | — | — | — | 17.38 | — |
| Cash Conversion Cycle | 0 | 0 | 0 | 12.37 | 22.12 | 42.94 | 104 | 0 | 298 | 5,432 | 1,430 | 3,136 |
| Working Capital Days | -8,882 | -1,659 | -514 | -804 | 55.3 | -176 | -1,251 | 4,849 | 221 | 4,530 | 917 | 3,177 |
| ROCE % | 0.35% | -5.84% | -0.57% | 0.57% | 4.17% | 5.96% | -5.1% | -8.54% | 28.48% | 0.57% | 11.84% | 1.02% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Genomic Valley Biotech insights
56 extracted metrics + investor summaries across FY12–FY26.
Documents
1
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Apr - Regulation 74(5) certificate submitted for quarter ended 31 March 2026. 14 Apr - Regulation 74(5) certificate submitted for quarter ended 31 March 2026.
2
Disclosure Under Regulation 31(4) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulation, 2011
3 Apr - FY26 Reg 31(4) filing: promoters declared no encumbrance as of 31 March 2026. 3 Apr - FY26 Reg 31(4) filing: promoters declared no encumbrance as of 31 March 2026.
3
Disclosure Under Regulation 31(4) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulation, 2011
1 Apr - Promoters declare no encumbrance on shares during FY ended March 31, 2026. 1 Apr - Promoters declare no encumbrance on shares during FY ended March 31, 2026.
4
Closure of Trading Window
24 Mar - Trading window closed from 01-Apr-2026 until 48 hours after audited results for year ended 31-Mar-2026. 24 Mar - Trading window closed from 01-Apr-2026 until 48 hours after audited results for year ended 31-Mar-2026.
Frequently Asked Questions about Genomic Valley Biotech
What does Genomic Valley Biotech Ltd do?
Incorporated in 2001, Genomic Valley Biotech Ltd is in the business of Horticultural and Agricultural products, and is also adding activities in Human Genomic[1]
Where is Genomic Valley Biotech Ltd (539206) listed?
Genomic Valley Biotech Ltd trades as GENOMICVALLEYBIOTECHLTD on the NSE and under code 539206 on the BSE.
Which sector does Genomic Valley Biotech Ltd belong to?
Genomic Valley Biotech Ltd is classified under the Healthcare sector, in the Biotechnology industry.
What is the market capitalisation of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd has a market capitalisation of ₹9.6 Cr, which places it in the Small Cap band.
What is the PE ratio of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd trades at a PE ratio of 450.00, on earnings per share of ₹0.42, against a book value of ₹12.85 per share.
What is the 52-week high and low of Genomic Valley Biotech Ltd?
Over the last 52 weeks Genomic Valley Biotech Ltd has traded between ₹20.1 and ₹41.
What is the Return on Equity (ROE) of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd reported a return on equity of 9.13%. Its debt-to-equity ratio is 0.00.
Company Information
Incorporated in 2001, Genomic Valley Biotech Ltd is in the business of Horticultural and Agricultural products, and is also adding activities in Human Genomic[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/539206.md for Genomic Valley Biotech Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.